SAN FRANCISCO: Just days after Biogen Inc. revealed promising early data from an experimental Alzheimer’s treatment, new research from the Mayo Clinic may revive a long-running debate over whether the drug industry is focusing on the right target in developing therapies to treat the disease. Read More »

AUSTIN: Actinogen has received confirmation from an independent Dose Escalation Committee that its lead drug candidate, Xanamem, when dosed at 10mg, satisfies safety, tolerability and pharmacokinetic metrics.

This now allows for a dose escalation to 25mg for the next cohort of 8 participants.

Full story

DALLAS: A pre-clinical study published this week suggests that focused ultrasound may hold a key to providing a non-invasive, non-pharmaceutical approach to treating Alzheimer’s disease.

Researchers demonstrated that combining the injection of microbubbles and applying ultrasound across the brain using a system from Philips Research Read More »

LISBON: A group of scientists from the Portuguese university Universidade Nova (UNL) who are researching Alzheimer’s, a neurodegenerative disease, were awarded a prize by bank Santander Totta/UNL.

The scientists aim to use methods involving genetic reprogramming of human cells. By transforming normal neurons into neurons Read More »